Results 311 to 320 of about 3,106,622 (403)
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement +12 more
wiley +1 more source
Breakdown of C3 complement and IgG in peritonitis exudate-pathophysiological aspects and therapeutic approach [PDF]
Billing, A. +5 more
core
This work presents ARC‐3D, a soft 3D model that recreates how brain support cells, called astrocytes, react to oxidative stress. The system visualizes rapid calcium changes and inflammatory signals, and shows how the drug KDS12025 can protect cells from damage. ARC‐3D offers a simple, reliable way to study early drivers of brain inflammation.
Ju‐Kang Kim +6 more
wiley +1 more source
Peptomer Linkers Enable Kinetic Control over Co‐Delivery of Multiple Chemotherapeutics
A key challenge in combinatorial chemotherapeutic drug delivery is independent control over release kinetics, especially with drugs of similar size and structure. Here, peptoid substitutions to proteolytically degradable peptides enabled the design of fast and slow‐releasing drug linkers.
Carolyn M. Watkins +3 more
wiley +1 more source
This review explores the evolving role of microneedle systems in psoriasis management, highlighting their potential for enhanced drug delivery, diagnosis, and disease monitoring. It also discusses unmet clinical needs for psoriasis management and technical challenges, while outlining strategic directions to advance microneedle integration into routine ...
Fatma Moawad +3 more
wiley +1 more source
Co-occurrence of Alpha-1 Antitrypsin Deficiency (AATD) and Common Variable Immunodeficiency (CVID): A Case Report. [PDF]
Aynaci A +4 more
europepmc +1 more source
A Hit Prioritization Strategy for Compound Library Screening Using LiP-MS and Molecular Dynamics Simulations Applied to KRas G12D Inhibitors. [PDF]
Absar F +7 more
europepmc +1 more source

